News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UCB Group to Launch Epilepsy Drug in Autumn
June 27, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS, June 27 (Reuters) - Shares in UCB SA jumped on Friday as the Belgian pharmaceutical group said it aimed to launch its new epilepsy drug Vimpat in the autumn, after winning a green light from the European Medicines Agency.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Insights
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
October 5, 2026
·
6 min read
·
Jennifer C. Smith-Parker
FDA
US government launches AI-driven programs to overhaul clinical trials
October 1, 2026
·
4 min read
·
Gabrielle Masson
Insights
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
October 1, 2026
·
1 min read
·
Jennifer C. Smith-Parker
FDA
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
September 30, 2026
·
3 min read
·
Heather McKenzie
